Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study

BACKGROUND: Albuvirtide (ABT), a fusion inhibitor against human immunodeficiency virus (HIV) infection, has good efficacy and tolerability for HIV treatment. However, there is a paucity of data regarding ABT-based regimen as second-line therapy. This current study evaluated the efficacy and safety o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liyu, Dai, Hua, Wang, Jiayi, Wang, Ming, Ma, Yuanji, Ma, Fanghua, Li, Changmin, Bai, Lang, Du, Lingyao, Tang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652537/
https://www.ncbi.nlm.nih.gov/pubmed/36388832
http://dx.doi.org/10.21037/atm-22-4369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652537/
https://www.ncbi.nlm.nih.gov/pubmed/36388832
http://dx.doi.org/10.21037/atm-22-4369

Ejemplares similares